There was, for example, a significant increase in the CD11b+ myeloid population in IL-10 deficient mice and mice treated with anti-IL-10/IL-10R neutralizing antibodies when compared to controls, indicating a difference in the tumor microenvironment due to IL-10 depletion. This evidence concerns the gene ITGAM and neoplasm.